Not a good buy right now for an impatient buyer: trend is still bearish (SMA_200 > SMA_20 > SMA_5) and odds skew to further downside over the next week/month.
Near-term sentiment is pressured by fresh securities-law allegations and multiple recent analyst downgrades/price-target cuts.
Oversold/near-support setup (RSI low, price near S1 ~10.84) can produce bounces, but there is no Intellectia buy signal today to prioritize an aggressive entry.
If you must act immediately, this is an avoid/sell setup rather than a buy; the cleaner “prove-it” catalyst is the upcoming earnings (2026-02-11 pre-market).
Technical Analysis
Trend: Bearish structure with moving averages stacked down (SMA_200 > SMA_20 > SMA_5) indicating persistent downtrend.
Momentum: MACD histogram at -0.154 (below zero) but negatively contracting → selling pressure may be easing, not reversing.
RSI_6: 27.784 (weak/near-oversold conditions) → bounce potential exists, but still within a downtrend.
Levels: Pre-market ~11.00 is just above S1 10.837 (key near-term support); next support S2 10.403. Overhead resistance: Pivot 11.54, then R1 12.243.
Intellectia Proprietary Trading Signals: - AI Stock Picker: no signal on given stock today. - SwingMax: No signal on given stock recently.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning/Sentiment: Open Interest put/call = 2.91 (heavy put open interest) → defensive/bearish positioning or hedging.
Flow today: Volume put/call = 0.29 (more calls than puts traded) → short-term speculative call interest, but it contrasts with the heavier bearish OI backdrop.
Volatility: IV 30d ~53.54 with IV percentile ~73.2 → elevated options pricing; event/uncertainty premium is meaningful.
Activity: Today’s volume vs 30d avg ~10.84 and OI build (today vs OI avg ~138%) → notable positioning into upcoming catalysts (notably earnings).
Technical Summary
Sell
7
Buy
4
Positive Catalysts
with low RSI can produce a reflex rally if selling exhausts.
Neutral/Negative Catalysts
News/legal overhang: investigations and a federal securities lawsuit alleging misleading disclosures/competitive weakness (negative sentiment catalyst).
Business headwinds: reports of market share losses and margin headwinds; “no quick fix” commentary from analysts.
Quant/pattern read-through: similar-pattern stats imply downside bias (-2.09% next week, -5.11% next month).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $1.6238B, down -5.28% YoY (continued top-line contraction).
Profitability: Net income -$711.8M (down -1331.49% YoY) and EPS -1.04 (down -1400% YoY) → major deterioration.
Margins: Gross margin 32.42%, down -1.52% YoY → margin compression trend is negative into the next print.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: ratings have moved materially more cautious/bearish from mid-Dec 2025 into early Jan 2026, with several downgrades.
Key changes: Evercore downgraded to In Line (PT $12 from $14); TD Cowen kept Hold but cut PT to $12; Jefferies downgraded to Underperform (PT $9 from $12); BofA downgraded to Neutral (PT $13); Nephron downgraded to Sell (PT $8).
Wall Street pros: potential 2026 upside if life science tools spending normalizes and expectations are already reset.
Wall Street cons: highlighted market share losses, margin headwinds, and lack of near-term catalyst—overall skew is negative/defensive.
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.3 USD with a low forecast of 8 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 12.3 USD with a low forecast of 8 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
9 Hold
2 Sell
Hold
Current: 10.790
Low
8
Averages
12.3
High
17
Current: 10.790
Low
8
Averages
12.3
High
17
TD Cowen
Hold
downgrade
$14 -> $12
AI Analysis
2026-01-07
Reason
TD Cowen
Price Target
$14 -> $12
AI Analysis
2026-01-07
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Avantor to $12 from $14 and keeps a Hold rating on the shares. The firm adjusted targets in the life science tools space as part of a Q4 outlook. While the bar is higher for the Q4 results following the recent share rallies, many companies "already soft guided" 2026, the analyst tells investors in a research note. TD believes this sets room for upside in 2026.
Evercore ISI
Outperform -> In Line
downgrade
$14 -> $12
2026-01-05
Reason
Evercore ISI
Price Target
$14 -> $12
2026-01-05
downgrade
Outperform -> In Line
Reason
Evercore ISI downgraded Avantor to In Line from Outperform with a price target of $12, down from $14.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AVTR
